Sodium- and chloride-dependent glycine transporter 1

Sodium- and chloride-dependent glycine transporter 1, also known as glycine transporter 1, is a protein that in humans is encoded by the SLC6A9 gene which is promising therapeutic target for treatment of diabetes and obesity.

Selective inhibitors
Elevation of extracellular synaptic glycine concentration by blockade of GlyT1 has been hypothesized to potentiate NMDA receptor function in vivo and to represent a rational approach for the treatment of schizophrenia and cognitive disorders. Several drug candidates have reached clinical trials.
 * ASP2535
 * Bitopertin (RG1678), which has entered phase II trials for the treatment of schizophrenia
 * Iclepertin (BI 425809) by Boehringer Ingelheim which is thought to improve cognitive impairment due to schizophrenia
 * Org 25935 (Sch 900435)
 * PF-03463275 (in phase II trial)
 * Pesampator (PF-04958242) by Pfizer
 * Sarcosine which is thought to improve cognitive impairment due to schizophrenia

Pathological mutations
Mutations of the gene may cause a severe metabolic disorder discovered in 2016 and called glycine encephalopathy with normal serum glycine (OMIM 617301), also known as GlyT1 encephalopathy.